Prostate Test Articles & Analysis: Older
8 articles found
While Movember is not just about prostate cancer, it is a great place to start; prostate cancer is the second most common cancer among men worldwide1, and the second leading cause of cancer death in American men.2 In the UK, more than 52,000 men are diagnosed with prostate cancer every year on average – which is 143 men every day, according ...
The ClarityDX Prostate® test provides patients and physicians with an accurate prediction of clinically significant prostate cancer to support decision-making and improve health outcomes for men suspected of having prostate cancer. ...
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have ...
” Recently, Nanostics announced positive results from the clinical validation study of its lead prostate cancer diagnostic test, ClarityDX Prostate®, showing 94% sensitivity, 37% specificity, 49% positive predictive value, and 90% negative predictive value for predicting clinically significant (grade group ≥2) ...
Summary Nanostics' clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions A top-ranked research institute in the Northeast US will now partner with Nanostics' by recruiting patients for the ...
Summary This study is designed to determine the accuracy of the blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater than 3 and no higher than 10 ...
The Yukon chapter of Ride For Dad says a new blood test developed by an Alberta-based company could save the lives of men at risk of prostate cancer. (iStock/Getty Images) A bio-technology company based in Alberta is testing a new process that could result in fewer Yukon men travelling out of territory for prostate cancer ...
Summary OTraces, in collaboration with the Johns Hopkins Medical Center, Brady Urology Institute (JHMC), performed a blinded validation study on OTraces prostate cancer (PCa) detection products. The blinded validation project involves two phases, and the first has been completed: Phase I: Blinded third party validation of the test for men with aggressive PCa, ...